• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Chardan Capital Markets Llc sold $725,162 worth of shares (342,136 units at $2.12) (SEC Form 4)

    7/2/24 6:34:54 PM ET
    $WENA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $WENA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    CHARDAN CAPITAL MARKETS LLC

    (Last) (First) (Middle)
    ONE PENNSYLVANIA PLAZA, SUITE 4800

    (Street)
    NEW YORK NY 10119

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ANEW Medical, Inc. [ WENA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/28/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/28/2024 S 47,000 D $2.5341(1) 1,579,500 D(2)
    Common Stock 07/01/2024 S 115,136 D $2.0638(3) 1,464,364 D(2)
    Common Stock 07/02/2024 S 180,000 D $2.0469(4) 1,284,364 D(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    CHARDAN CAPITAL MARKETS LLC

    (Last) (First) (Middle)
    ONE PENNSYLVANIA PLAZA, SUITE 4800

    (Street)
    NEW YORK NY 10119

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Chardan Securities LLC

    (Last) (First) (Middle)
    ONE PENNSYLVANIA PLAZA, SUITE 4800

    (Street)
    NEW YORK NY 10119

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    GROSSMAN JONAS

    (Last) (First) (Middle)
    1 EAST PUTMAN AVENUE, 4TH FLOOR

    (Street)
    GREENWICH CT 06830

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Urbach Steven

    (Last) (First) (Middle)
    ONE PENNSYLVANIA PLAZA, SUITE 4800

    (Street)
    NEW YORK NY 10119

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    PROPPER KERRY

    (Last) (First) (Middle)
    ONE PENNSYLVANIA PLAZA, SUITE 4800

    (Street)
    NEW YORK NY 10119

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.38 to $2.71, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
    2. This Form 4 is being filed by Chardan Capital Markets LLC ("CCM"). Chardan Securities LLC ("Chardan Securities") is the sole Class A Member and 99% owner of CCM and as such has voting and investment discretion with respect to the Common Stock held of record by CCM and may be deemed to have beneficial ownership of the Common Stock held directly by CCM. Each of Jonas Grossman, Steven Urbach and Kerry Propper is a member of Chardan Securities, and as such has voting and investment discretion with respect to the Common Stock held of record by CCM and may be deemed to have beneficial ownership of the Common Stock held directly by CCM. Each of Mr. Grossman, Mr. Urbach and Mr. Propper disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
    3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.80 to $2.495, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
    4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.90 to $2.30, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
    Chardan Capital Markets LLC, By: /s/ Steven Urbach, Manager 07/02/2024
    Chardan Securities LLC, By: /s/ Steven Urbach, Manager 07/02/2024
    /s/ Jonas Grossman 07/02/2024
    /s/ Steven Urbach 07/02/2024
    /s/ Kerry Propper 07/02/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $WENA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $WENA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WENA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.

      NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Board of ANEW MEDICAL, INC. (NASDAQ:WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ:KLTO), and has launched a new website, www.klothoneuro.com. The name and ticker change will have no impact on current shareholders, and there is no action required on their part. The new name embodies the Company's commitment to strategically direct its core investments of time and financial resources toward the multibillion-dollar market opportunities for the company's patented Klotho gene technology assets in the neurosciences sector. Through its exclusive worldwide license, the company's patent protected secr

      9/17/24 6:30:00 AM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy

      NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer's and Parkinson's disease. ANEW has secured exclusive worldwide rights and issued patents in the USA, Canada, Europe, Hong Kong and China, covering the secreted form of Klotho, known scientifically as s-KL. Klotho is often referred to as "the anti-aging gene." It is named after the

      9/4/24 7:46:07 AM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility

      NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW's balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in long-term debt not only clears ANEW's balance sheet but also significantly increases stockholder equity, positioning the company for future growth and investment opportunities. It also eliminates $600,000 in annual interest payments owed by the company. The avera

      8/26/24 5:00:00 AM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WENA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Chardan Capital Markets Llc sold $725,162 worth of shares (342,136 units at $2.12) (SEC Form 4)

      4 - ANEW Medical, Inc. (0001907223) (Issuer)

      7/2/24 6:34:54 PM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Chardan Capital Markets Llc claimed ownership of 1,626,500 shares (SEC Form 3)

      3 - ANEW Medical, Inc. (0001907223) (Issuer)

      7/1/24 6:14:59 PM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WENA
    SEC Filings

    See more
    • SEC Form EFFECT filed by ANEW MEDICAL INC.

      EFFECT - ANEW Medical, Inc. (0001907223) (Filer)

      9/19/24 12:15:16 AM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-1 filed by ANEW MEDICAL INC.

      S-1 - ANEW Medical, Inc. (0001907223) (Filer)

      9/5/24 12:31:49 PM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ANEW MEDICAL INC. filed SEC Form 8-K: Leadership Update

      8-K - ANEW Medical, Inc. (0001907223) (Filer)

      8/30/24 4:21:06 PM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WENA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ANEW MEDICAL INC.

      SC 13G - ANEW Medical, Inc. (0001907223) (Subject)

      6/27/24 5:36:14 PM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WENA
    Financials

    Live finance-specific insights

    See more
    • ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke ("TTS")

      NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or the "Company") (NASDAQ:WENA) announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke ("TTS") regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines. Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering to doctor visits and medication protocols. Alternatives to needle/syringes have been introduced including creams, patches, inhalers, liquid autoinjectors, but they have significant cost and formulation limitations for topical applications. Th

      8/21/24 5:00:00 AM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WENA
    Leadership Updates

    Live Leadership Updates

    See more
    • ANEW MEDICAL, INC. Appoints New CFO

      NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company's Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was the former CFO of Redwoods Acquisition Corp into which ANEW merged. "Jeff LeBlanc is a highly experienced senior executive, and we are absolutely delighted to welcome him to our team," commented, Dr. Joseph Sinkule, the Founder, Chairman and CEO of ANEW. "Jeff has over 20 years of experience in managing financial ope

      8/19/24 5:00:00 AM ET
      $WENA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care